U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07513948) titled 'Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura' on Jan. 19.
Brief Summary: Data about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce. Therefore, the investigators aim at collecting evidence on a larger number of patients through a collaborative, international study.
Study Start Date: Oct. 01, 2025
Study Type: OBSERVATIONAL
Condition:
Thrombotic Thrombocytopenic Purpura, Acquired
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Published by HT Digital Content Services with pe...